Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · IEX Real-Time Price · USD
26.76
-0.32 (-1.18%)
At close: Jul 19, 2024, 4:00 PM
26.81
+0.05 (0.19%)
Pre-market: Jul 22, 2024, 4:27 AM EDT
Akero Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Akero Therapeutics stock have an average target of 41.43, with a low estimate of 30 and a high estimate of 56. The average target predicts an increase of 54.82% from the current stock price of 26.76.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 11, 2024.
Analyst Ratings
The average analyst rating for AKRO stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 12, 2024 |
| Wolfe Research | Wolfe Research | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jun 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +86.85% | Jun 11, 2024 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $50 → $38 | Buy | Maintains | $50 → $38 | +42.00% | May 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.88
from -2.89
EPS Next Year
-4.27
from -3.88
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 70.6M | 121.9M | 389.8M |
| Avg | n/a | n/a | 35.7M | 39.5M | 178.3M |
| Low | n/a | n/a | n/a | n/a | 61.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 241.1% | 887.8% |
| Avg | - | - | - | 10.5% | 351.9% |
| Low | - | - | - | - | 54.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.03 | -3.53 | -3.82 | -1.89 | 1.23 |
| Avg | -3.88 | -4.27 | -4.01 | -1.84 | 1.19 |
| Low | -4.55 | -4.72 | -4.27 | -1.76 | 1.15 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.